South Africa Pharmaceutical Registrations Expiring: May - July 2026 Analysis

A recent analysis reveals five active pharmaceutical registrations are slated for expiry in South Africa within the next 90 days, specifically between May and July 2026. This critical period demands immediate attention from regulatory teams to prevent potential supply chain disruptions and ensure continued market access for these products.

Overview of Upcoming Expiries

The impending expirations involve products from three distinct holders, including key generics that play a role in patient access. The table below details these registrations:

Drug	Holder	Country	Expiry Date	Reg No
ABITIG (each tablet contains: abiraterone acetate 250,0 mg)	Ranbaxy Pharmaceutical (Pty) Ltd	South Africa	22 Jun 2026	51/21.12/0508
ABARINE (each tablet contains: abiraterone acetate 250,0 mg)	Ranbaxy Pharmaceutical (Pty) Ltd	South Africa	22 Jun 2026	51/21.12/0509.508
SERALOP 5 mg/ml (none)	Ando Pharma (Pty) Ltd	South Africa	29 Jun 2026	49/2.6.5/0213
DUREEP 30 (none)	Ascend Laboratories (Pty) Ltd	South Africa	27 Jul 2026	50/1.2/0206
DUREEP 60 (none)	Ascend Laboratories (Pty) Ltd	South Africa	27 Jul 2026	50/1.2/0207

Critical Expirations: Focus on Key Generics

Among the expiring registrations, particular attention should be given to the abiraterone acetate products: ABITIG and ABARINE, both held by Ranbaxy Pharmaceutical (Pty) Ltd. Abiraterone acetate is a vital medication used in the treatment of prostate cancer. As generics, these products often play a crucial role in improving patient access to critical therapies by offering more affordable alternatives. The lapse of these registrations could potentially impact treatment options and cost-effectiveness for patients requiring this specific oncological medication in South Africa.

Similarly, DUREEP 30 and DUREEP 60, held by Ascend Laboratories (Pty) Ltd, represent other generic formulations. While the specific indication is not provided, the consistent presence of multiple dosage strengths (30 and 60) often suggests a broad utility or a drug requiring careful titration, making its sustained availability important.

Regulatory Implications of Lapsed Registrations

Allowing a pharmaceutical product registration to lapse in South Africa carries significant regulatory and commercial ramifications. The South African Health Products Regulatory Authority (SAHPRA) requires that all pharmaceutical products marketed in the country hold a valid registration. If a registration expires without renewal, the product effectively loses its legal authorization to be sold, distributed, or even imported into South Africa.

Key consequences include:

• Market Withdrawal: Products with lapsed registrations must be immediately removed from the market. This can lead to substantial financial losses due to unsold inventory, recall costs, and disposal expenses.
• Supply Chain Disruptions: For essential medicines or widely used generics, a sudden withdrawal can create immediate shortages, impacting patient care and public health, and potentially leading to a black market for the product.
• Reputational Damage: Companies that fail to manage their renewals effectively can suffer damage to their reputation among healthcare providers, patients, and regulatory bodies.
• Complex Re-registration Process: Re-registering a product after its initial registration has lapsed is often a far more arduous and time-consuming process than a timely renewal. It may involve submitting a new application, which can be as demanding as the initial registration process, potentially taking months or even years. This delay means significant periods of market absence.
• Loss of Market Share: Competitors with similar products are likely to capitalize on the absence of a lapsed product, making it difficult for the original product to regain its market position even if it is eventually re-registered.

Regulatory bodies like SAHPRA emphasize proactive compliance. Companies are expected to have robust internal systems for tracking expiry dates and initiating renewal procedures well in advance of the deadline. The 90-day window highlighted by this data serves as a critical period for regulatory teams to ensure all necessary documentation is prepared and submitted for a seamless renewal process.

Navigating the Renewal Process

Pharmaceutical companies operating in South Africa must navigate SAHPRA's renewal requirements meticulously. This typically involves submitting updated product information, proof of good manufacturing practice (GMP) compliance, and any required post-market surveillance data, alongside the relevant fees. The complexity and turnaround times for renewals necessitate early preparation to avoid last-minute complications.

AfriReg Pro helps regulatory teams automate the tracking of critical deadlines like registration expirations across African markets. Our platform provides real-time data and alerts, enabling proactive management of regulatory portfolios and mitigating the risks associated with lapsed registrations and non-compliance.